Stock report · Delisted · Nasdaq
Inozyme Pharma Inc (INZY)
4.00USD Delisted Final close · Jun 30, 2025
INZY no longer trades. Inozyme Pharma Inc was delisted from the Nasdaq in June 2025.
All prices on this page are historical. The last trade was on June 30, 2025, at $4.00.
INZY stock price history
Final trading statistics
- Final close
- $4.00
- Final trading day
- Jun 30, 2025
- Market cap at delisting
- $258.25M
- Shares outstanding
- 64.56M
- Final 52-week range
- $0.72 – $6.24
- Avg. volume (final 3 mo.)
- 2,226,011
- All-time high
- $30.20 · Sep 2020
- All-time low
- $0.82 · Apr 2025
- Return since IPO
- -77.2%
- Beta
- 2.29
- Book value / share
- $0.49
- Price / book
- 8.11
About Inozyme Pharma Inc
Inozyme Pharma was a clinical-stage biopharmaceutical company working on treatments for rare diseases that harm bone health and blood vessel function. Its lead candidate, INZ-701, was an engineered recombinant ENPP1 fusion protein aimed at ENPP1 and ABCC6 deficiencies, calciphylaxis, and patients with end-stage kidney disease on hemodialysis.
The company also worked on Next Gen ERT for ossification of the posterior longitudinal ligament (OPLL) and on a gene therapy related to the PPi-Adenosine Pathway. It held a license agreement with Yale University for certain therapeutic and preventive products.
Inozyme was incorporated in 2015 and based in Boston, Massachusetts. Its shares were delisted from the Nasdaq in June 2025, with the last trade on June 30, 2025 at $4.00.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA
- Employees
- 67
- IPO date
- July 24, 2020
- Delisted
- June 30, 2025
- SEC CIK
- 1693011
Inozyme Pharma financials before the delisting
The last 5 fiscal years Inozyme Pharma reported as a public company, fiscal year ending December.
INZY revenue and net income
INZY earnings per share
INZY annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$102.0M | −$1.63 |
| FY2023 | $0.00 | −$71.2M | −$1.37 |
| FY2022 | $0.00 | −$65.4M | −$1.89 |
| FY2021 | $0.00 | −$56.4M | −$2.39 |
| FY2020 | $0.00 | −$55.8M | −$10.99 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Inozyme Pharma stock FAQ
What happened to Inozyme Pharma stock?
Inozyme Pharma Inc was delisted from the Nasdaq in June 2025. The final close was $4.00 on June 30, 2025.
Can I still buy INZY stock?
No. INZY is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on June 30, 2025.
What was the last price of INZY?
INZY last closed at $4.00 on June 30, 2025, which valued the company at about $258.25M.
How did Inozyme Pharma do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Inozyme Pharma reported revenue of $0.00 and net income of −$102.0M.
When did Inozyme Pharma go public?
Inozyme Pharma shares started trading on July 24, 2020.
INZY no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.